A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM.
Verstovsek S, et al. Among authors: rumi e.
Cancer. 2014 Feb 15;120(4):513-20. doi: 10.1002/cncr.28441.
Cancer. 2014.
PMID: 24258498
Free PMC article.
Clinical Trial.